NCT05087888: MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must be planning to undergo fractionated radiotherapy to the brain
Exclusions: Patients with prior radiation to the brain

Comments are closed.

Up ↑